Renal cell carcinoma, VHL-associated

From - A Hematology Oncology Wiki
Jump to navigation Jump to search
Section editor
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA

Social-twitter-icon.png arkhaki

Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page
1 variants on this page

All lines of therapy

Belzutifan monotherapy

back to top


Study Years of enrollment Evidence
Awaiting publication (MK-6482-004) 2018-ongoing Phase II (RT)

Note: dosing information is from the FDA labeling.

Targeted therapy

Continued indefinitely


  1. MK-6482-004: NCT03401788